Peptide target therapy of NF-κB, chemical inhibitor of Bcl-2 and mdr1 gene expression in Acute Myeloid Leukemia (AML) cell line

Acute myeloid leukemia (AML) is a hematological malignancy that the cause of death in adults. In this cancer over expression of Bcl-2 and P-glycoprotein are the two cause of resistance. NF-κB, a transcription factor that enhance expression of the panel of gene, include the two mentioned above molecules. NF-κB is a good target for treatment of cancer and overcoming to drug resistance in cancer therapy. ABT-737 is a novel anti Bcl-2 small molecule drug that is has strong potency to chemotherapy as a new drug.

Peptide target therapy of NF-κB, chemical inhibitor of Bcl-2 and mdr1 gene expression in Acute Myeloid Leukemia (AML) cell line Keywords:

AML , HL 60 , ABT-737 , NBD peptide , mdr1